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Abstract Mucopolysaccharidosis type IVA (MPS IVA) or
Morquio syndrome is a multisystem disorder caused by
galactosamine-6-sulfatase deficiency. Skeletal manifesta-
tions, including short stature, skeletal dysplasia, cervical
instability, and joint destruction, are known to be asso-
ciated with this condition. Due to the severity of these
skeletal manifestations, the non-skeletal manifestations
are frequently overlooked despite their significant con-
tribution to disease progression and impact on quality of
life. This review provides detailed information regarding
the non-skeletal manifestations and suggests long-term
assessment guidelines. The visual, auditory, digestive, car-
diovascular, and respiratory systems are addressed and over-
all quality of life as measured by endurance and other
functional abilities is discussed. Impairments such as corneal
clouding, astigmatism, glaucoma, hearing loss, hernias, hepa-
tomegaly, dental abnormalities, cardiac valve thickening
and regurgitation, obstructive sleep apnea, tracheomala-
cia, restrictive and obstructive respiratory compromise,
and muscular weakness are discussed. Increased aware-
ness of these non-skeletal features is needed to improve
patient care.
Introduction
MPS IVA (OMIM #253000), also known as Morquio syn-
drome, is an autosomal recessive lysosomal storage disease
first described in 1929 (Morquio 1929; Brailsford 1929).
Morquio syndrome can refer to either MPS IVA or MPS
IVB, which, while similar, are caused by defects in different
enzymes. MPS IVA is the focus of this review. The inci-
dence of MPS IVA differs among different populations;
reported rates range from 1 in 76,000 live births in Northern
Ireland (Nelson 1997) to 1 in 640,000 live births in western
Australia (Nelson et al. 2003).
MPS IVA is caused by mutation of the gene encoding
galactosamine-6-sulfatase (GALNS, EC 3.1.6.4), which
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results in impaired catabolism of two glycosaminogly-
cans (GAGs), keratan sulfate and chondroitin-6-sulfate
(Dorfman et al. 1976; Glössl and Kresse 1982). As in
other MPS disorders, nondegraded GAGs accumulate in
lysosomes to a degree that interferes with cellular func-
tion. The tissue distribution of the particular GAGs
accumulated in an MPS disorder is reflected in the clinical
presentation of the disease. In the case of MPS IVA,
accumulation of keratan sulfate and chondroitin-6-
sulfate manifests mainly as short stature and skeletal
dysplasia (Wraith 1995) with bone deformity being the
most common initial symptom (Montaño et al. 2007).
Additional compromised systems include the visual, au-
ditory, digestive, cardiovascular, and respiratory systems
(Northover et al. 1996). The brain and spinal cord are not
believed to be directly impacted by GAG accumulation in
MPS IVA as normal intelligence is preserved (Wraith 1995).
However, patients have a high risk of developing neurological
complications due to skeletal abnormalities (Nelson and
Thomas 1988).
There is a wide spectrum of disease progression
among MPS IVA–affected individuals. A high degree
of genetic heterogeneity is likely responsible for this
phenotypic variety. More than 100 different mutations
have been identified in the GALNS gene (Tomatsu et al.
2005). Clinical presentations of the disease range from
a severe, rapidly progressing phenotype to a slowly
progressing phenotype. Onset of disease symptoms
commonly occurs prior to 1 year of age in rapidly pro-
gressing patients or as late as the second decade of life
in slowly progressing patients (Montaño et al. 2007).
Diagnosis is typically based on clinical examination,
skeletal radiographs, urinary GAG tests, and the enzy-
matic activity of GALNS in blood cells or fibroblasts
(Montaño et al. 2007). Further confirmation can be
provided by identification of the molecular defect in the
GALNS gene.
Once diagnosed, MPS IVA requires a multi-disciplinary
approach to patient care. Management of skeletal mani-
festations and the associated neurological complications
is critically important for patients with MPS IVA. How-
ever, the other aspects of the disease also significantly
impact patient lives. MPS IVA–induced dysfunctions in
the visual, auditory, digestive, cardiovascular, and respi-
ratory systems can severely affect patient quality of life
by reducing endurance, limiting participation in various
activities, and increasing dependence on care givers.
With the goal of establishing a better understanding of
the non-skeletal manifestations of MPS IVA and im-
proving patient quality of life, we systematically discuss
the non-skeletal systems affected by MPS IVA, present




Diffuse corneal clouding is the most common ocular finding
in MPS IVA, although it occurs to a lesser extent and is
more slowly progressive than in other MPS diseases (Danes
1973). A retrospective review of 20 patients with MPS IV
(subtype A or B not specified), ages 1–65 years, identified
10 eyes with no corneal clouding, 17 eyes with mild corneal
clouding, 4 with moderate corneal clouding, and 4 with
severe corneal clouding (corneal clouding was not graded
in 5 eyes); the severity of corneal clouding was generally
related to increasing age of the patient and resulted in
reduction in visual acuity (Couprie et al. 2010). The diffuse,
finely granular corneal deposits are best visualized with slit-
lamp biomicroscopy but when more severe, can be observed
with a bright penlight held at an oblique axis to the eye. The
corneal deposits may also interfere with examination of
other ocular structures, e.g., the trabecular meshwork, the
retina, and the optic nerve. Electron microscopy has shown
that the corneal clouding is primarily due to fibrillogranular,
as well as multimembranous, membrane-bound inclusions
in the keratocytes, representing GAGs and complex lipids/
glycolipids, respectively; in addition, extracellular granular
material has been reported (Ghosh and McCulloch 1974;
Iwamoto et al. 1990). This disruption of the normal corneal
lamellae results in light scattering and can cause the patient
to be photosensitive (Leslie et al. 2005). While the inclu-
sions can also be found in the conjunctiva, sclera, trabecular
meshwork, and retinal pigment epithelium, the primary
effect is in the cornea (Iwamoto et al. 1990).
Glaucoma or ocular hypertension seems to be unusual in
MPS IVA (Davis and Currier 1934). Case reports of corneal
clouding and glaucoma in 35-year-old and 36-year-old sib-
lings with MPS IV (subtype A or B not specified) found that
the glaucoma was open angle (likely due to accumulation of
GAG in the trabecular meshwork over time, obstructing
aqueous outflow), was associated with visual field constric-
tion, and was managed with topical medications (Cahane et
al. 1990). This is in contrast to the closed/narrow angle
glaucoma that has been reported in MPS VI (Cantor et al.
1989; Sato et al. 2002). Electron microscopy has shown
distended trabecular endothelial cells with a thickened base-
ment membrane in MPS IVA. The inclusions in the trabec-
ular meshwork are primarily multimembranous, whereas
other types of MPS have more fibrillogranular inclusions,
perhaps explaining the reduced prevalence of ocular hyper-
tension and glaucoma in individuals with MSP IVA (Iwamoto
et al. 1990; Leslie et al. 2005).
While visual acuity is generally better in MPS IVA com-
pared with other types of MPS, corneal clouding, refractive
errors, glaucoma, and cataracts can affect visual acuity as
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the patient matures. Patients with MPS IV (subtype A or B
not specified) tend to have astigmatism in addition to myo-
pia and hyperopia (Couprie et al. 2010), in contrast with
hyperopia alone as has been reported in patients with other
types of MPS (Fahnehjelm et al. 2010). Different types of
cataracts or lens opacities have been reported in MPS IV
(subtype A or B not specified): punctate lens opacities in six
individuals ages 6–45 years, “small” lens opacities in a 9-year-
old, nuclear sclerosis in a 65-year-old, and lamellar/zonular
cataracts in three individuals ages 8–15 years (Couprie et al.
2010; Iwamoto et al. 1990; Olsen et al. 1993). With progres-
sion of the cataracts, visual acuity may be affected.
Optic nerve atrophy may rarely occur due to glaucoma,
optic nerve infiltration, or retinal dystrophy (Dangel and
Tsou 1985; Abraham et al. 1974; Käsmann-Kellner et al.
1999). When retinal dystrophy is present, the patient may
note nyctalopia (night blindness), and funduscopic exami-
nation can show constricted arterioles (Abraham et al. 1974;
Dangel and Tsou 1985; Käsmann-Kellner et al. 1999). Elec-
troretinography is needed to assess retinal function and
make a diagnosis of a retinal dystrophy, typically reported
as a reduction in the scotopic responses, in addition to
possible delay in photopic implicit times (Dangel and Tsou
1985; Käsmann-Kellner et al. 1999; Abraham et al. 1974).
Electroretinography has rarely been documented in MPS
IVA, perhaps related to infrequent electrophysiology, absent
or mild symptoms, or to the relative sparing of the retina and
central nervous system as compared to other MPS disorders.
One study, reporting reduced and delayed b-wave scotopic
responses in a 43-year-old with MPS IV (subtype A or B not
specified), noted that the retinal changes in these patients are
insidious and might not be seen in younger patients (Dangel
and Tsou 1985). Indeed, essentially normal retina and cen-
tral nervous system tissue has been reported in MPS IVA
with histopathology (Koto et al. 1978), and some clinical
reports have documented normal electroretinography into
the fourth decade of life (Cahane et al. 1990; Gills et al.
1965; Leung et al. 1971). Interestingly, no inclusions in
retinal neurons and rare fibrillogranular inclusions in the
retinal pigment epithelial cells were reported by one study
(Iwamoto et al. 1990). The two cases with MPS IVA in this
study, ages 18 and 19 years, also showed no optic nerve
abnormalities on post-mortem examination (Iwamoto et al.
1990). Lastly, similar to other types of MPS, the eyes may
appear prominent (pseudoexopthalmos) in MPS IVA due to
shallow orbits (Käsmann-Kellner et al. 1999).
Auditory system
As in all forms of MPS, reduction in hearing in patients with
MPS IVA can be attributed to multiple causes. Firstly,
conductive hearing loss can be present and is most likely
secondary to recurrent upper respiratory tract infections and
frequent serous otitis media (Schlieier and Steubel 1976).
Conductive loss can also be caused by deformity of the
ossicles (Barranger and Cabrera-Salazar 2002). Secondly,
sensorineural loss may occur as a result of GAG accumula-
tion. Abnormal auditory brainstem response (ABR) results
have been described and are thought to be a combination of
middle ear, cochlear, eighth nerve, and lower brainstem
pathology (Leroy and Crocker 1966).
Hearing loss in MPS IVA usually begins in adolescence,
however the conductive element caused by frequent upper
respiratory tract infections and serous otitis media can be
present anytime from birth onwards. The hearing loss is
progressive, and once the sensorineural element is present,
it can be severe and is almost universally found in patients
who survive beyond the second decade (Bredenkamp et al.
1992; Keleman 1977).
Most patients with MPS IVA have a “mixed hearing loss”
attributed to the combination of a conductive element and a
sensorineural element. Ventilation tubes can be used to treat
aspects of the conductive hearing loss, but the patient is
likely to still have a conductive loss if there is ossicular
involvement and most patients will have an underlying pro-
gressive sensorineural loss.
Abnormal vestibular function has also been reported in a
patient with MPS IV (subtype A or B not specified) (Sataloff
et al. 1987).
Digestive system
The digestive system is also affected by MPS IVA.
According to data from the International Morquio A
Registry conducted by the International Morquio Orga-
nization, some MPS IVA patients have reported hernias
among their initial and current symptoms (Tomatsu et
al. 2011). Although umbilical and inguinal hernias are
the most common hernia types in patients with MPS
disorders (Ashworth et al. 2006), an MPS IV (subtype A
or B not specified) patient with bilateral diaphragmatic hernias
has also been reported (Nursal et al. 2000).
Another element of the digestive system that may be
affected is the liver. Although not as common as in other
MPS disorders, hepatomegaly has been reported in patients
with MPS IVA (Nelson et al. 1988) and was reported as an
initial and current symptom in the International Morquio A
Registry (Tomatsu et al. 2011). Hepatosplenomegaly has
also been reported (Holzgreve et al. 1981), although it
seems to be less common and was not found in all studies
in which it was evaluated (Nelson et al. 1988). The liver
manifestations are likely a direct result of GAG accumula-
tion as keratan sulfate and chondroitin-6-sulfate are known
to accumulate in the liver (Minami et al. 1979). Interesting-
ly, when analyzed, the keratan sulfate found in the liver of a
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patient with MPS IVA appeared to be structurally similar to
the keratan sulfate found in bone (Minami et al. 1983).
In addition to hernias and hepatomegaly, generalized
stomach problems were also reported by patients in the
International Morquio A Registry (Tomatsu et al. 2011).
While gastrointestinal dysfunction and chronic diarrhea
have been reported in other MPS disorders (Wraith 1995;
Sibilio et al. 2009), the specific stomach problems experi-
enced by MPS IVA patients have not been described in the
literature.
Overall, digestive system manifestations appear to be less
prominent in MPS IVA than in other MPS disorders. How-
ever, there is one exception: dental abnormalities are a
particular feature of MPS IVA (James et al. 2012). Due to
the integral role of teeth in the digestive system and the
importance of oral health in maintaining quality of life
(Sheiham 2005), dental abnormalities are included here
even though they could also be classified as a skeletal
manifestation. Through in situ hybridization of a day 1
mouse incisor it has been shown that GALNS mRNA is
most abundant in secretory ameloblasts indicative of a de-
velopmental disturbance during the secretory stage of enam-
el formation (Yamakoshi et al. 2002). This disturbance
manifests as dental abnormalities in patients with MPS
IVA including spaced dentition (Kuratani et al. 2005), point-
ed cusps (Rolling et al. 1999; Kinirons and Nelson 1990),
spade-shaped incisors (Rolling et al. 1999; Kinirons and
Nelson 1990), dental pitting with a band of increased
porosity just below the surface of the enamel correlating
to the positions of striae of Retzius (Rolling et al.
1999), enamel hypoplasia (Kuratani et al. 2005; Rolling
et al. 1999; Kinirons and Nelson 1990), developmental
abnormalities of primary and permanent dentition (James et al.
2012), and an increased risk of dental caries (James et al.
2012). In addition, a scanning electron microscopy study has
revealed that MPS IV teeth possess a thin layer of amorphous
material between the normal prismatic enamel and the dentine
surface, believed to be the result of poorly mineralized tissue
produced at the earliest stages of amelogenesis (Lustmann
1978). A recent study found that patients with MPS IVA have
increased caries rates and enamel defects as compared to both
the general population and patients with other MPS disorders
(James et al 2012). In concurrence with this finding, there
appears to be a marked difference in the orientation distribu-
tion of enamel crystallites between enamel affected by MPS
IVA and healthy enamel (Al-Jawad et al. 2011).
Cardiovascular system
Cardiac involvement in MPS IVA has previously been
thought to be mild (Northover et al. 1996) or uncommon
(Montaño et al. 2007). Accurate understanding of the cardi-
ac findings in MPS IVA patients has been hampered by
small patient numbers (Schieken et al. 1975; Gross et al.
1988), absence of supporting biochemical documentation of
diagnosis (Schieken et al. 1975), failure to differentiate
between MPS IVA and MPS IVB (Schieken et al. 1975;
Gross et al. 1988; Wippermann et al. 1995; Dangel 1998;
Mohan et al. 2002; Fesslová et al. 2009; Lael et al. 2010),
and evolving cardiac ultrasound technology (Schieken et al.
1975; Gross et al. 1988; John et al. 1990; Dangel 1998). The
single cardiac ultrasound study specifically addressing MPS
IVA lacks the color flow Doppler technology that improves
the detection of valve stenosis and insufficiency (John et al.
1990). Conversely, the studies that do utilize color Doppler
technology do not differentiate between MPS IVA and MPS
IVB (Schieken et al. 1975; Gross et al. 1988; Wippermann
et al. 1995; Dangel 1998; Mohan et al. 2002; Fesslová et al.
2009; Lael et al. 2010).
Remarkably, despite the absence of color Doppler, cardi-
ac valve disease was found to be quite common in the single
study devoted to MPS IVA (John et al. 1990). Five of the 10
patients studied (50%) had mitral valve regurgitation (one of
whom had mitral valve stenosis as well), 30% had aortic
valve regurgitation, and 20% had both mitral and aortic
regurgitation in conjunction with left ventricular hypertro-
phy. Aortic and/or mitral valve thickening was present in
40% of patients. The average age of patients within the
study was 12.5 years although the range was broad (3–
40 years). Valve dysfunction occurred in all three adults,
but was also present in two patients aged 11 and 13 years.
Studies that did not differentiate between MPS IVA and
MPS IVB showed a comparable incidence of aortic and
mitral valve thickening (40%) and valve stenosis (7–9%)
but a somewhat lesser incidence of valve regurgitation (17–
26%) (Supplemental Table 1).
It is generally thought that cardiac valves most affected in
the MPS syndromes are those associated with dermatan
sulfate deposition (Dangel 1998). However, keratan sulfate
and chondroitin-6-sulfate are both found within normal car-
diac valves (Latif et al. 2005), so it is not surprising that the
gross and histological appearances of the MPS IVA cardiac
valves are similar to the patterns found in MPS I, II, and VI.
Valve thickening, seen on cardiac ultrasound, has been
found to be nearly as common in patients who do not
accumulate dermatan sulfate as in those who do (Lael et
al. 2010). All MPS IVA cardiac valves may show GAG
deposition, although the left-sided cardiac valves are more
severely affected. Excess GAG is present within MPS IV
(subtype A or B not specified) cardiac valve tissue obtained
during valve replacement (Barry et al. 2006) and at post
mortem examination (Ireland and Rowlands 1981). Mitral
valve chordae are thick and shortened, valve edges are
thickened and rolled. The aortic valve cusps are thickened
throughout and some fusion of the commissures has been
noted (Ireland and Rowlands 1981). Characteristic
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vacuolated cells deep within the valve tissue (likely valvular
interstitial cells), appear to be present as well (Barry et al.
2006; Factor et al. 1978). The myocardium can be hyper-
trophied (Ireland and Rowlands 1981), and coronary intimal
sclerosis may be present (Factor et al. 1978), even at a
young age.
Respiratory system
Alterations in respiratory function are common in patients
with MPS IVA (Montaño et al. 2007). Respiratory impair-
ment occurs due to direct involvement of respiratory tissues
and as a consequence of involvement in other body systems.
Thus, the etiology for respiratory impairment is multifacto-
rial and attributable to upper and lower airway obstruction,
cervical myelopathy, and chest wall restriction. Alteration in
growth and development provides an additional mechanism
for respiratory impairment due to the short stature and
skeletal dysplasia that is frequently noted in these patients
(Tomatsu et al. 2011). Patients with MPS IVA are at in-
creased risk for complications that include recurrent infec-
tions, progressive loss of respiratory function, sleep
disordered breathing, and ultimately respiratory failure
(Montaño et al. 2007; Tomatsu et al. 2011; Pelley et al.
2007).
As in other MPS diseases, pulmonary involvement
occurs in part due to GAG accumulation throughout the
respiratory system (Peters et al. 1985; Semenza and Pyeritz
1988; Walker et al. 2003). GAG accumulation is prominent
in the upper airways and tonsils leading to an increased risk
for development of obstructive sleep apnea (Montaño et al.
2007). During wakefulness, collapse of the upper airway has
been documented upon neck flexion (Pritzker et al. 1980).
Hyperextension of the neck (the sniff position) may occur in
order to maintain airway patency. GAG accumulation has
also been documented in the intrathoracic airways (Semenza
and Pyeritz 1988). Tracheal and bronchial wall abnormali-
ties have been noted on post mortem examination (Walker et
al. 2003). Tracheomalacia and bronchomalacia with associ-
ated airway collapse have been documented upon fiber optic
bronchoscopy (Walker et al. 2003). Recognition of this
complication is imperative as airway obstruction may persist
after therapeutic tracheostomy due to persistent airway col-
lapse distal to the tip of the endotracheal tube (Pelley et al.
2007). Lastly, although the incidence and magnitude of
GAG accumulation in pulmonary parenchyma are un-
known, if present, this complication would further compro-
mise pulmonary function and gas exchange.
Respiratory compromise also occurs in patients with
MPS IVA due to involvement of the chest wall and neuro-
muscular systems (Buhain et al. 1975; Sly 1980; Ashraf et
al. 1991). Chest wall deformities including pectus carinatum
and kyphoscoliosis can limit lung expansion and produce a
restrictive impairment that manifests as a reduction in lung
volume. Displacement of the diaphragm into the thoracic
cavity may occur due to short stature coupled with hepatic
and/or splenic enlargement, further compromising respira-
tory function. In addition to the previously stated chest wall
abnormalities, atlantoaxial instability and spinal cord com-
pression are common in patients with MPS IVA (Tomatsu et
al. 2011) and may result in respiratory muscle weakness.
Spinal cord compression can to lead to phrenic nerve dys-
function and inspiratory muscle weakness potentially
impairing patient ability to maintain ventilation in the set-
ting of reduced chest wall compliance. Furthermore, impair-
ment of the expiratory muscle strength due to thoracic and/
or lumbar involvement impairs cough and clearance of
secretions, thereby predisposing patients to infections. The
combined effects of these alterations are recognized mech-
anisms for development of respiratory failure in otherwise
healthy subjects and, therefore, are likely to result in re-
duced ventilation rates and development of respiratory fail-
ure in patients with MPS IVA.
Respiratory function is also altered by the short stature
and skeletal dysplasia characteristic of patients with MPS
IVA. In other MPS disorders associated with short stature
(e.g., MPS VI), patient height is the primary determinant of
vital capacity (Swiedler et al. 2005). In addition, improve-
ment in pulmonary function during enzyme replacement
therapy (ERT) in other MPS disorders is frequently associ-
ated with growth and increased stature (Harmatz et al.
2010). While corresponding data in patients with MPS
IVA are not available, a similar pattern is likely to occur,
suggesting that measures targeted to promote growth and
development may have a beneficial effect on the respiratory
dysfunction characteristic of MPS IVA.
Sleep disordered breathing (SDB) is common in all MPS
diseases (Semenza and Pyeritz 1988) and may precede
development of overt respiratory failure during wakeful-
ness. Ventilatory abnormalities during sleep include obstruc-
tive sleep apnea as a consequence of GAG accumulation in
the upper airway and sustained hypoventilation due to the
chest wall deformity and/or respiratory muscle weakness.
If chronic respiratory insufficiency and sleep disordered
breathing remain unrecognized and untreated, progression
to development of cor pulmonale may occur. The combined
primary and secondary effects of GAG accumulation in
patients with MPS IVA can result in impairment of respira-
tory function to a degree that can ultimately lead to respira-
tory failure and early demise (Pelley et al. 2007; Walker et
al. 2003).
Overall quality of life
As the MPS IVA disease process progresses, quality of life
for the patient declines. Patients become progressively more
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dependent on care givers as deteriorating vision, hearing,
oral health, respiratory and cardiac function, muscular
strength, and endurance make routine daily activities increas-
ingly difficult to accomplish. A description of the endurance
and mobility challenges faced by MPS IVA patients is pro-
vided online as supplemental material (S1). Ultimately, in the
absence of treatment, patient quality of life continuously
decreases as the disease progresses.
Recommended assessments
Visual system
Annual eye examinations are recommended in MPS IVA
and should include slit-lamp biomicroscopy of the cornea,
measurement of intraocular pressure, assessment of refrac-
tive error, and examination of the posterior segment. Older
patients may undergo electroretinography to detect the rod-
cone retinal dystrophy that has been reported. If vision is
reduced, evaluation with low-vision aids should be consid-
ered. When glaucoma is detected, or keratoplasty or cataract
surgery is required, more frequent examinations may be
necessary.
Auditory system
Annual auditory assessments are recommended from birth
(or diagnosis). Otoacoustic emissions (OAEs) can be used to
ascertain outer hair cell function, however, due to the likely
presence of middle ear effusions, OAEs are unlikely to be
recordable, so assessment using ABR is recommended as an
appropriate neonatal test. If hearing impairment is discov-
ered, management is dependent on the severity and type of
hearing loss. A conductive hearing loss for instance can be
treated either with ventilation tubes if the cause is middle ear
fluid, or to avoid surgery, a bone conduction hearing aid can
be used, if this is fitted onto a soft band, which can be
particularly good for young babies and infants.
Beyond infancy, regular audio behavioral testing should
be carried out annually due to the progressive nature of the
hearing impairment, both to check for any conductive ele-
ments and also because the risk of developing a sensorineu-
ral loss increases with age. From around 8 months to the age
of 2.5years, the child should be able to perform behavioral
testing such as visual reinforcement audiometry (VRA),
although this requires the child to be able to sit supported
around the waist and have good head control. Full ear specific
testing with bone conduction is possible when performing
VRA at this age and is highly recommended. Once the child
is 3 years of age, conventional hearing checks such as play
audiometry should take place at least annually and more
regularly if hearing aids have been issued.
Digestive system
Overall digestive health should be assessed at diagnosis and
then as clinically indicated. Annual imaging by ultrasound,
CT, or MRI to determine liver size may be useful. The oral
health component of digestive health should ideally be
assessed every 6 months, but, at minimum, should be assessed
at least annually. Clinicians and dentists should be aware that
due to enamel defects and the common difficulties these
patients experience in maintaining good oral health, MPS
IVA patients have an increased risk of developing caries and
may be considered as candidates for fissure sealing. It is also
important to ensure patients are receiving adequate fluoride
supplementation as that is the only chemical element known
to be effective for caries prevention (Bromo et al. 2011).
Attention to oral health is of particular importance in this
patient population especially as dental caries can contribute
to the risk of infective endocarditis (Franco et al. 1996), and
antibiotic prophylaxis may be indicated in some cases before
invasive surgery.
Cardiovascular system
Upon establishment of diagnosis, individuals with MPS IVA
should undergo baseline cardiac evaluation, including aus-
cultation, electrocardiogram, and cardiac ultrasound to as-
sess cardiac involvement. Although cardiac murmurs may
be present, their absence does not rule out the presence of
cardiac valve pathology, and noninvasive testing should still
be performed. The electrocardiogram will document the
presence of normal atrioventricular conduction as well as
the absence of acute ischemia or previous myocardial injury.
Cardiac ultrasound will provide an understanding of the
underlying anatomy and function of the MPS IVA heart. The
cardiac ultrasound should include the following:
1. M-mode determination of cardiac chamber dimensions
and wall thicknesses and shortening fraction
2. B-mode assessment of the thickness of cardiac valves,
the measurement of aortic sinus and sinotubular ridge
dimensions, the left ventricular ejection fraction, and the
identification of regional wall motion abnormalities, if
present
3. Doppler interrogation of all cardiac valves for stenosis
and/or regurgitation, of both great vessels; and finally
estimation of right ventricular systolic and pulmonary
artery diastolic pressures
Depending upon the initial cardiac evaluation, cardiac
follow-up should be performed every 1–3 years and prior
to any proposed major operative intervention(s). Should
concern for potential coronary artery involvement be raised
by symptoms or resting noninvasive findings, noninvasive
stress imaging should be performed.
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Respiratory system
There are many methods available for respiratory assess-
ment. Lung function and SDB should be evaluated in all
patients at diagnosis and then as indicated. Children can
generally perform simple respiratory function testing from
the age of 5, and it is suggested that from age 8 assessment
of respiratory function be performed at least annually. How-
ever, due to the width of the phenotypic spectrum of MPS
IVA, identification of the most appropriate methods of as-
sessment needs to be done on an individual patient basis.
For lung function studies age, size, and fitness are all
important considerations. As patients with MPS IVA exhibit
a restrictive and an obstructive element of respiratory com-
promise, both aspects need to be assessed. A brief discus-
sion of assessment methods potentially appropriate for
patients with MPS IVA is provided here, a more in-depth
version is available online as supplemental material (S2). It
should be noted that lung function tests are not diagnostic;
instead they describe the pattern of a disease. Therefore,
serial measurements are recommended to follow the natural
progress of the disease or assess the impact of treatment.
Assessment of airflow limitation can be divided into
active and passive measurements. Spirometry is the most
common test utilized to assess airflow limitation. This test
requires the active participation of the patient to determine
the maximum volume of air that can be exhaled in the first
second of a forced expiratory maneuver starting at full lung
inflation (forced expiratory volume in 1 s, FEV1). However,
due to the need to assess very young patients and the
common lack of endurance in older patients, passive meas-
urements may be appropriate. One such measurement is
impulse oscillation (IOS), where airway resistance is
assessed utilizing a speaker to impose external oscillating
pressure and airflow impulses over the subject’s tidal breath-
ing. A second type of passive measurement, multiple-breath
inert gas washout (MBW), has the potential to be used
across all age ranges (including infants). Airway disease is
identified using an index of the uniformity of airflow distri-
bution throughout the airways. Since MBW measurements
vary minimally with age, MBW should be particularly use-
ful for following children longitudinally (Robinson et al.
2009) as would be desirable in following disease progres-
sion in a patient with MPS IVA.
Additional measurements should include assessment of
lung size. Spirometry is a readily available technique uti-
lized to measure the vital capacity (VC; the maximum
amount of air that can be inhaled/exhaled from full inflation
to maximum deflation) providing an indication of the size of
the lungs. The “gold standard” assessment of lung restric-
tion is by measurement of total lung capacity (TLC). This
can be assessed by a variety of techniques either physiolog-
ical, including whole body plethysmography, gas (typically
helium) dilution, and nitrogen washout, or by radiographic
means [conventional chest radiographs or computerized to-
mography (CT)]. In an ideal world both plethysmography
and gas dilution/nitrogen washout tests should be per-
formed, however this may be limited by the availability of
equipment and local expertise. In patients with limited abil-
ity to co-operate (such as children 2–5 years of age), radio-
graphic techniques may offer an alternative method of
assessment (Clausen 1997).
Sleep studies should be performed in addition to lung
function assessments. Performance of a formal sleep study
is recommended at diagnosis and should be repeated when-
ever SDB is suspected. Symptoms suggestive of SDB, such
as apneas, gasping respirations, snoring, difficult wakening,
daytime somnolence, and restless sleep, should be assessed
as part of the clinical evaluation of all patients at least
annually. Overnight sleep studies can be used to both diag-
nose the type and severity of SDB and to evaluate nocturnal
ventilatory treatments for the underlying respiratory disorder.
All patients should be asked about symptoms of respira-
tory insufficiency such as dyspnea; however, symptoms
may be minimally perceived when exercise capacity is lim-
ited secondary to reduced endurance. Objective assessment
of CO2 retention is best accomplished by analysis of arterial
blood gases, however, this test may not be readily available
in some outpatient settings. Alternatively, capnography may
be used as a surrogate measure, or elevation of serum
bicarbonate concentration in venous blood can be used as
a screening test for chronic hypoventilation; an elevated
serum bicarbonate concentration (>27 mEq/L) may be a
marker of renal compensation for chronic CO2 retention.
Lastly, spiral CT of the chest can be useful in detecting
tracheomalacia and should be considered at least before
major surgery to uncover upper airways abnormalities (Shih
et al. 2002).
Overall quality of life
To track and manage quality of life, patients with MPS IVA
should see a specialist physiotherapist annually to carry out
evaluation of impairment, including determination of range
of motion, muscle strength, and resulting activity and par-
ticipation limitations.
Annual endurance assessments are recommended as a
method of following patient mobility and potential for inde-
pendence. Because endurance measurements allow for the
clinical evaluation of multiple systems simultaneously, they
are an effective method of assessing overall disease progres-
sion (McDonald et al. 2010). Reductions in endurance alter
patients’ functional capacity, which can lead to decreased
independence and therefore impact on their quality of life.
Patients should also undergo evaluation by a physiother-
apist and endurance assessments prior to and after surgeries
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to enable clinicians to establish a baseline and track post-
operative progress.
Recommended endurance measurements for patients
with MPS IVA include the six-minute walk test (6MWT)
as described by the American Thoracic Society (ATS 2002)
and the three-minute stair climb (3MSC) as described for
patients with MPS VI (Harmatz et al. 2005). A description
of these tests as well as a discussion of complications and
limitations is available online as supplemental material (S3).
Interventions and outcomes
Visual system
Conservative treatment for reduced vision and photosensi-
tivity due to opacification of the cornea in MPS IVA
includes filtering or photochromic spectacles and a brimmed
hat, visor, or cap (Northover et al. 1996). When corneal
clouding is marked, keratoplasty may be required. Important
considerations include other possible causes of reduced
vision (Käsmann-Kellner et al. 1999), other sensory disabil-
ities (e.g., hearing loss), neurodevelopmental status, and
availability of an anaesthesia team skilled in working with
individuals with MPS (Belani et al. 1993; Geetha et al.
2010). Recurrence of corneal opacity after 10 months was
reported in a 12-year-old boy with MPS IVA (Käsmann-
Kellner et al. 1999). Others have reported reopacification of
the transplanted cornea in MPS IVA as well (Maumenee
1978; Iwamato et al. 1990). However, clear corneal grafts
have been reported 2 years (Leslie et al. 2005) and 6 years
(Couprie et al. 2010) after keratoplasty. Reopacification of
the corneal graft may occur more frequently in MPS disor-
ders in which keratan sulfate accumulates, compared with
MPS disorders in which heparan sulfate or dermatan sulfate
accumulates (Käsmann-Kellner et al. 1999). Despite reopa-
cification of the cornea, keratoplasty may provide substan-
tial improvement in daily function for a variable period of
time in patients with MPS IVA. Interestingly, corneal cloud-
ing has also reportedly improved following successful bone
marrow transplantation (Desai et al. 1983).
When visually significant cataracts occur in patients with
MPS IVA (typically later in life), cataract surgery with
placement of an intraocular implant can restore vision if
other irreparable causes of vision loss are absent (Couprie
et al. 2010). Glaucoma rarely occurs in patients with MPS
IVA and may initially be managed medically. With progres-
sive optic nerve cupping and/or visual field loss, filtration
surgery may be required. When reduced vision cannot be
further improved with refractive correction, patients may
benefit from low-vision aids, in addition to high contrast
and enlarged print material. However, there is no current
treatment to specifically ameliorate the optic atrophy and
retinal dystrophy that have occasionally been reported in
this disease. With periodic reassessment, the patient’s qual-
ity of life can be maximized by treatment of the ocular
abnormality (e.g., keratoplasty or glaucoma treatment) or
providing options to enhance the use of residual vision.
Auditory system
By the first decade of life, most patients with MPS IVA may
be expected to have either a sensorineural hearing loss or a
mixed hearing loss, which is a combination of sensorineural
and conductive hearing loss (Riedner and Levin 1977).
Ventilation tubes can be offered to treat conductive hear-
ing loss from retained middle ear fluid. These are placed
under general anaesthetic, where a small incision behind the
tympanic membrane can be made (myringotomy) to drain
the accumulated fluid. A small ventilation tube often called
a grommet may then be inserted, which allows air to enter.
Grommets will eventually fall out, and once they have fallen
out the tympanic membrane will heal, and the fluid can re-
occur. T-tubes are a longer lasting type of grommet, and in
view of the anaesthetic risks for individuals with MPS IVA,
and the risk of the reoccurrence of the middle ear fluid, may
be preferable to use on the first occasion.
Bone conduction hearing aids are a nonsurgical option
for the first few years of life and can be worn either on a
headband or a soft band. These are preferable to air conduc-
tion hearing aids if the hearing loss fluctuates, which is often
the case with conductive hearing losses caused by middle
ear fluid.
As there is a progressive sensorineural element to the
hearing loss in MPS IVA, bone conduction hearing aids
may cease to be the most appropriate forms of amplification.
Post-aural hearing aids may be needed to deliver the gain
required for the patient to access the speech frequencies and
ideally will work best if the fluctuating conductive element
of the hearing loss is reduced by use of ventilation tubes.
Digestive system
Hernias can be repaired surgically, and due to poor
connective tissue, special techniques may be needed to
prevent recurrence. Approximately 6% of the patients in
the International Morquio A Registry reported undergo-
ing herniorrhaphy; the mean age was 8 years at the time
of surgery (Montaño et al. 2007). As with any surgical
procedure in this patient population, anaesthesia should
be performed with caution, and to prevent potential
complications, anaesthesiologists should have experience
working with MPS patients due to the difficult airway, short
stature, restricted head movement, and other features of this
multisystem disease.
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Table 1 Recommended assessments for non-skeletal aspects of MPS IVA






Slit-lamp biomicroscopy of cornea ● ● More frequent examinations may be




● ● More frequent examinations may be
necessary if glaucoma is detected
Assessment of refractive errora ● ●
Examination of posterior segmentb ● ●
Electroretinography under
scotopic and photopic conditions
At onset of symptoms (night blindness or
constriction of visual field) or signs
(arteriolar attenuation, retinal pigment






OAE At diagnosis in neonates
VRA At diagnosis and annually for patients
between 8 months and 3 years old
Digestive system
Clinical evaluation of digestive
health
● As clinically indicated
Imaging by ultrasound, CT, or
MRI to determine liver size
●
Evaluation of oral health by a
dentist
● Ensure adequate fluoride supplementation
and consider fissure sealing of dentition
Cardiovascular system
Auscultation ● ● ●
Electrocardiogram ● ● ●
Cardiac ultrasound ● ● ●
Noninvasive stress imaging As clinically indicated
Respiratory system
Spirometry to assess VC and FEV1 ● ●
IOS When spirometry measurements are not
feasible
MBW When following disease progression from
an early age is desired
TLC determined by gas dilution or
washout methods (≥8 years old)
● ●
TLC determined by
plethysmography (≥8 years old)
If equipment and expertise are available
TLC determined by radiographic
techniques
In place of other TLC determination
methods in patients with limited ability to
co-operate
Clinical evaluation of symptoms
suggestive of SDB
● ●
Overnight sleep studies ● As clinically indicated
Analysis of arterial blood gases ● ● As clinically indicated




If an analysis of arterial blood gases and
capnography are not available
Spiral CT of the chest ●
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Regarding oral health, parents or care givers should
be given advice on maintaining their child’s oral hy-
giene. Regular preventative maintenance is highly rec-
ommended to avoid the need for interventions requiring
general anaesthesia.
Cardiovascular system
Defining the medical management for the valvulopathies that
may occur in MPS IVA is beyond the scope of this review.
Existing guidelines for the medical management of cardiac
valve disease have been constructed for common valves dis-
orders found in normal adults, such as aortic stenosis from
calcification of a bicuspid aortic valve (Bonow et al. 2006,
2008), but not for the MPS diseases specifically. These guide-
lines are a reasonable starting point but do not address all of
the other organ systems (pulmonary, skeletal) that may influ-
ence the outcome for individuals with MPS IVA.
Similarly, indications for cardiac valve replacement in
MPS IVA have not been defined. Noncardiac factors, such
as cervical instability and respiratory function, should be
factored into the timing of valve replacement. Familiarity
with the airway, respiratory, and CNS issues of MPS
patients is important in the anaesthetic and perioperative
management of patients with MPS IVA. Intraoperative mon-
itoring of ongoing peripheral nervous system function
should be part of the standard intraoperative protocol. Suc-
cessful aortic valve replacement has been reported in adults
with MPS IVA (Pagel and Almassi 2009; Nicolini et al.
2008). The long term failure of the Ross procedure (in
which the patient’s own pulmonary valve is used to replace
the stenotic or regurgitant aortic valve) has been reported in
MPS IVB (Barry et al. 2006). Finally, bone marrow
transplantation has been performed in two children with
MPS IV (subtype A or B not specified): a 5 year old
(Gatzoulis et al. 1995) who demonstrated no improvement
in cardiac status and an 8 year old (Kato et al. 1986) in
whom cardiac follow-up was not provided.
Respiratory system
Multiple interventions are required to maintain optimal func-
tional status, and patients may benefit from involvement of a
pulmonologist, preferably with experience managing patients
with MPS disorders. Therapy should be targeted based on the
underlying abnormalities and pulmonary status of each indi-
vidual. All patients should receive regular vaccinations,
including pneumococcus and influenza vaccinations. Treat-
ment of respiratory tract infections should be early and
aggressive. Impairment in secretion clearance due to chest
wall abnormalities and weakened cough can be addressed by
both manual and mechanical techniques. Inhaled bronchodi-
lators can be used in conjunction with these airway clearance
techniques. Bronchodilators and corticosteroids (inhaled and/
or oral) may be useful if concurrent asthma is present.
Abnormal sleep study results indicate intervention is
needed and upper airways should be evaluated. Removal
of tonsils and adenoids, if enlarged, could help with upper
airway obstruction. While removal of abnormal deposits is
sometimes useful, it should be left to those with experience
in this procedure as upper airway scar tissue could compro-
mise the already small airway (Yeung et al. 2009). Upper
airway obstruction and progressive airway collapse can also
be managed by respiratory support and CPAP (continuous
positive airways pressure), which acts as a dynamic airway
stent. For patients with nocturnal hypoventilation, the use of
Table 1 (continued)





Overall quality of life
Evaluation of impairment by a
physiotherapist
● ● Prior to and after surgical procedures to
track patient progress and as clinically
indicated
6MWT (if developmentally and
physically able)
● ● Prior to and after surgical procedures to
track patient progress and as clinically
indicated
3MSC (if developmentally and
physically able)
● ● Prior to and after surgical procedures to
track patient progress and as clinically
indicated
OAE Otoacoustic emissions, VRA visual reinforcement audiometry, VC vital capacity, FEV1 forced expiratory volume in 1 s, IOS impulse
oscillation, MBW multiple-breath inert gas washout, TLC total lung capacity, SDB sleep disordered breathing, 6MWT six-minute walk test,
3MSC three-minute stair climb
a Correction of refractive error may include filtering spectacle lenses if photosensitivity is present. Bifocals or reading glasses may be needed if
vision is reduced
b Evaluate optic nerve (edema, atrophy, cupping), vessels (arteriolar attenuation), and retina (pigmentary change)
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noninvasive ventilator support systems (e.g., bilevel positive
airway pressure, BiPAP) can dramatically improve quality
of life. Patients with abnormal posturing (the sniff position)
may require specialized attention to ensure that the mask
used is comfortable and adequate. Supplemental oxygen can
be used if these methods do not fully correct the hypoxia,
but careful titration of the rate of oxygen administration and
monitoring of arterial carbon dioxide levels are required to
prevent oxygen-induced hypercapnia. Tracheostomy is some-
times needed especially if tracheomalacia is present but is a
particular problem in this cohort due to persistent airway
collapse distal to the tip of the endotracheal tube (Pelley et
al. 2007) and the patients’ preference for sleeping on their
stomachs. Sadly, uncontrolled respiratory failure is frequently
the event leading to death in these patients.
Overall quality of life
The current options for treating MPS IVA in a multisystemic
manner to address overall quality of life are limited. Although
bone marrow transplant is an option, the procedure has high
rates of morbidity and mortality due to infection, graft-versus-
host disease, and other complications (Tomatsu et al. 2011).
ERT has been used successfully in other MPS disorders
(Wraith et al. 2004; Muenzer et al. 2006; Harmatz et al.
2006), but it is not yet available for patients with MPS IVA.
However, ERT clinical trials for MPS IVA are currently un-
derway (http://clinicaltrials.gov), which may lead to ERT
becoming a treatment option in the future.
Currently, in the absence of an effective and safe sys-
temic treatment option, patients require extensive manage-
ment and regular intervention to maximize their quality of
life. Although their quality of life will continually decline over
their lifetime as the disease progresses, steps can be taken
along the way to keep patients active, pain free, and indepen-
dent for as long as possible. A brief discussion of some of
these steps is available online as supplemental material (S4).
Conclusions
Non-skeletal manifestations of MPS IVA, including the
visual, auditory, digestive, cardiovascular, and respiratory
system abnormalities, have a significant impact on patient
quality of life. Regular assessments of these systems are
recommended for all patients with MPS IVA (Table 1) to
facilitate timely intervention and maximize quality of life
potential.
Ophthalmologic abnormalities develop gradually, but if
regularly assessed, can be identified and usually corrected to
prevent impairment. The progressive and multifactorial de-
cline of auditory function is also likely to require interven-
tion. Maintaining a patient’s ability to see and hear by utilizing
visual and auditory system assessments and interventions
can help maintain patient functionality and independence.
Treating any dental disease early and performing preventative
dental maintenance are important in avoiding oral interven-
tions requiring general anaesthesia and maintaining overall
oral health and patient quality of life.
Assessment of cardiovascular and respiratory systems is
of paramount importance. Cardiovascular and respiratory
interventions can be life-saving in MPS IVA. Familiarity
with the cardiovascular and respiratory issues in MPS IVA
and appropriate baseline measurements are important during
operations and other medical procedures requiring sedation.
Respiratory complications in particular are often responsible
for patient losses.
The non-skeletal manifestations of MPS IVA are respon-
sible for significant morbidity and mortality in the MPS IVA
population. However, regular assessments and timely inter-
ventions can substantially improve patient outcomes.
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